Kynmobi Patent Expiration

Kynmobi is a drug owned by Sumitomo Pharma America Inc. It is protected by 19 US drug patents filed from 2020 to 2022. Out of these, 12 drug patents are active and 7 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 19, 2036. Details of Kynmobi's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959943 Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(11 years from now)

Active
US10449146 Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(11 years from now)

Active
US8846074 Sublingual films
Dec, 2031

(7 years from now)

Active
US8414922 Sublingual films
Dec, 2031

(7 years from now)

Active
US11419769 Sublingual films
Dec, 2031

(7 years from now)

Active
US9669021 Sublingual apomorphine
Jun, 2030

(5 years from now)

Active
US9044475 Sublingual apomorphine
Jun, 2030

(5 years from now)

Active
US10420763 Sublingual apomorphine
Jun, 2030

(5 years from now)

Active
US9669019 Sublingual apomorphine
Jun, 2030

(5 years from now)

Active
US9283219 Sublingual films
Jun, 2030

(5 years from now)

Active
US9326981 Sublingual apomorphine
Jun, 2030

(5 years from now)

Active
US10821074 Sublingual and buccal film compositions
Aug, 2029

(4 years from now)

Active
US8603514 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(7 months ago)

Expired
US8765167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(9 months ago)

Expired
US8663687 Film compositions for delivery of actives
Feb, 2023

(1 year, 9 months ago)

Expired
US10888499 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
Feb, 2022

(2 years ago)

Expired
US9855221 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(2 years ago)

Expired
US11077068 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(2 years ago)

Expired
US9931305 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Feb, 2022

(2 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Kynmobi's patents.

Given below is the list of recent legal activities going on the following patents of Kynmobi.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 03 Nov, 2023 US9326981
Payment of Maintenance Fee, 8th Year, Large Entity 15 Sep, 2023 US9283219
Payment of Maintenance Fee, 4th Year, Large Entity 24 Apr, 2023 US10449146
Payment of Maintenance Fee, 4th Year, Large Entity 24 Mar, 2023 US10420763
Change in Power of Attorney (May Include Associate POA) 10 Mar, 2023 US8414922
Change in Power of Attorney (May Include Associate POA) 10 Mar, 2023 US11419769
Change in Power of Attorney (May Include Associate POA) 10 Mar, 2023 US9283219
Change in Power of Attorney (May Include Associate POA) 10 Mar, 2023 US10959943
Change in Power of Attorney (May Include Associate POA) 10 Mar, 2023 US10449146
Correspondence Address Change 09 Mar, 2023 US10959943


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Kynmobi and ongoing litigations to help you estimate the early arrival of Kynmobi generic.

Kynmobi's Litigations

Kynmobi been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Kynmobi's patents.

Last updated on November 19, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Par Pharmaceutical, Inc.
US8603514 June, 2017 Terminated-Denied
(20 Oct, 2017)
MonoSol Rx, LLC Dr. Reddy’s Laboratories, Inc.
US8603514 November, 2016 Terminated-Settled
(06 Oct, 2017)
MonoSol Rx, LLC et al. Mylan Technologies, Inc. et al.
US8603514 May, 2016 Terminated-Denied
(05 Dec, 2016)
MonoSol Rx, LLC Dr. Reddy's Laboratories, Inc.
US8603514 December, 2015 Terminated-Denied
(23 May, 2016)
MONOSOL RX LLC Teva Pharmaceuticals USA Inc
US8765167 October, 2014 FWD Entered
(24 Mar, 2016)
MonoSol Rx, LLC. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Terminated-Settled
(24 Mar, 2016)
MonoSol Rx, LLC. et al. BioDelivery Sciences International, Inc.
US8765167 October, 2014 Terminated-Denied
(20 May, 2015)
MonoSol Rx, LLC. BioDelivery Sciences International, Inc.


FDA has granted some exclusivities to Kynmobi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Kynmobi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Kynmobi.

Exclusivity Information

Kynmobi holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Kynmobi's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 21, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Kynmobi's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Kynmobi's generic, the next section provides detailed information on ongoing and past EP oppositions related to Kynmobi patents.

Kynmobi's Oppositions Filed in EPO

Kynmobi has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15175258A May, 2019 D Young & Co LLP Granted and Under Opposition
EP10786915A May, 2016 LTS LOHMANN Therapie-Systeme AG Granted and Under Opposition
EP10786915A May, 2016 Generics (U.K.) Limited Granted and Under Opposition
EP11157819A Jun, 2014 Ahrens, Gabriele Patent maintained as amended
EP02782151A Jun, 2013 Acino Pharma AG Revoked
EP02782151A Jun, 2013 Germann, Sandra Revoked
EP02801042A Sep, 2012 Ahrens, Gabriele Patent maintained as amended
EP02801042A Sep, 2012 LTS LOHMANN Therapie-Systeme AG Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Kynmobi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Kynmobi's family patents as well as insights into ongoing legal events on those patents.

Kynmobi's Family Patents

Kynmobi has patent protection in a total of 25 countries. It's US patent count contributes only to 42.2% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Kynmobi.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Kynmobi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 19, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Kynmobi Generic API suppliers:

Apomorphine Hydrochloride is the generic name for the brand Kynmobi. 1 company has already filed for the generic of Kynmobi. Check out the entire list of companies who have already received approval for Kynmobi's generic





About Kynmobi

Kynmobi is a drug owned by Sumitomo Pharma America Inc. It is used for managing 'off' episodes in patients with Parkinson's disease. Kynmobi uses Apomorphine Hydrochloride as an active ingredient. Kynmobi was launched by Sumitomo Pharma Am in 2020.

Approval Date:

Kynmobi was approved by FDA for market use on 21 May, 2020.

Active Ingredient:

Kynmobi uses Apomorphine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Apomorphine Hydrochloride ingredient

Treatment:

Kynmobi is used for managing 'off' episodes in patients with Parkinson's disease.

Dosage:

Kynmobi is available in film form for sublingual use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
10MG FILM Discontinued SUBLINGUAL
20MG FILM Discontinued SUBLINGUAL
15MG FILM Discontinued SUBLINGUAL
25MG FILM Discontinued SUBLINGUAL
30MG FILM Discontinued SUBLINGUAL